制药巨头礼来宣布,将收购生物技术公司Atai Beckley。此举旨在强化其在精神健康领域的布局,特别是针对难治性抑郁症及其他复杂精神健康疾病的创新疗法开发。此次收购有望整合Atai Beckley在相关领域的研发管线与技术专长,加速潜在新疗法的问世进程。
制药巨头礼来宣布,将收购生物技术公司Atai Beckley。此举旨在强化其在精神健康领域的布局,特别是针对难治性抑郁症及其他复杂精神健康疾病的创新疗法开发。此次收购有望整合Atai Beckley在相关领域的研发管线与技术专长,加速潜在新疗法的问世进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.